| 000 | 01271 a2200385 4500 | ||
|---|---|---|---|
| 005 | 20250514020540.0 | ||
| 264 | 0 | _c20020128 | |
| 008 | 200201s 0 0 eng d | ||
| 022 | _a0028-0836 | ||
| 024 | 7 |
_a10.1038/414821a _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aMoller, D E | |
| 245 | 0 | 0 |
_aNew drug targets for type 2 diabetes and the metabolic syndrome. _h[electronic resource] |
| 260 |
_bNature _cDec 2001 |
||
| 300 |
_a821-7 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Review | ||
| 650 | 0 | 4 | _aAnimals |
| 650 | 0 | 4 |
_aDiabetes Mellitus _xdrug therapy |
| 650 | 0 | 4 |
_aDiabetes Mellitus, Type 2 _xdrug therapy |
| 650 | 0 | 4 | _aForecasting |
| 650 | 0 | 4 |
_aGlucose _xmetabolism |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aHypoglycemic Agents _xpharmacology |
| 650 | 0 | 4 |
_aInsulin _xmetabolism |
| 650 | 0 | 4 | _aInsulin Secretion |
| 650 | 0 | 4 | _aLipid Metabolism |
| 650 | 0 | 4 |
_aLiver _xdrug effects |
| 650 | 0 | 4 | _aMetabolic Syndrome |
| 650 | 0 | 4 | _aObesity |
| 650 | 0 | 4 |
_aReceptors, Cytoplasmic and Nuclear _xdrug effects |
| 650 | 0 | 4 | _aSignal Transduction |
| 650 | 0 | 4 |
_aTranscription Factors _xdrug effects |
| 773 | 0 |
_tNature _gvol. 414 _gno. 6865 _gp. 821-7 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1038/414821a _zAvailable from publisher's website |
| 999 |
_c11655573 _d11655573 |
||